At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro (Humalog) Following Single Dose Administration in Japanese Patients With Type 1 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating LY900014 and Insulin Lispro for Diabetes Mellitus, Type 1. Completed, enrolled 31 participants across 1 site.
Detailed Summary
This study will compare LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs will be given by injection under the skin of the abdomen. This study will be conducted in participants with type 1 diabetes to investigate how quickly and how much LY900014 is absorbed and the effect of LY900014 on blood sugar levels in comparison with insulin lispro. The study will last about 3 to 6 weeks for each participant, not including screening.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJan 2018
Enrollment StartFeb 2018
Primary CompletionJun 2018
Study CompletionJul 2018
TodayJul 2026
First PostedJan 23, 2018
Enrollment StartFeb 17, 2018
Primary CompletionJun 23, 2018
Study CompletionJul 12, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.4 years ago
Interventions
LY900014drug
Administered SC.
Insulin Lisprodrug
Administered SC.